At Mount Sinai, our Precision Urology™ approach to diagnosing prostate cancer involves the integration of multiple variables and imaging data in a decision support system. This collaboration is key in assuring men with prostate cancer of our commitment to a patient-centric, personalized diagnostic approach and excellent outcome, while minimizing the side effects of treatment. Precision Urology, developed by Dr. Ash Tewari, Chair of the Department of Urology and a world renowned robotic prostate cancer surgeon, reflects our utilization of advanced technologies and incorporation of molecular and genomic analysis to identify markers of aggressive disease. This allows us to rigorously stage disease to determine if intervention is needed and if so, tailor the treatment accordingly.
Our arsenal of Precision Urology tools and techniques include Artemis, an imaging device that allows 3D prostate visualization and tracking. By fusing multiparametric MRI with real-time ultrasound, abnormal or suspicious areas seen on the MRI can be tracked and targeted during a prostate biopsy. Artemis offers sophisticated recording of actual biopsy sites sampled, which can be reviewed at any time. Mount Sinai is one of a few facilities in New York City with an Artemis device.
3 Tesla (3T) Multiparametric Magnetic Resonance Imaging (MRI)
3T MRI is a state-of-the-art, non-invasive imaging modality that facilitates diagnosing, staging, and pre-operative planning for prostate cancer. Magnetic waves create images of the prostate and surrounding tissue. Using advanced computer algorithms, images can then be processed to predict where prostate cancer lesions are located.
NeuroSAFE™ allows the assessment of surgical margin for absence or presence of cancer intra-operatively, allowing the surgeon to perform adequate nerve sparing and resecting more tissue, if necessary to ensure oncological safety.
Our researchers are working to unravel the genetic factors linked to prostate cancer. Genetic screening can pick up mutations in an individual's genetic code that may increase the risk of advanced prostate cancer. We combine genetic information with advanced imaging and immunohistochemistry to determine prostate cancer risk and staging. We design prostate cancer screening plans tailored to each patient's risk profile.